Terms: = Prostate cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
209 results:
1. Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients.
Sibert NT; Kurth T; Breidenbach C; Wesselmann S; Feick G; Carl EG; Dieng S; Albarghouth MH; Aziz A; Baltes S; Bartolf E; Bedke J; Blana A; Brock M; Conrad S; Darr C; Distler F; Drosos K; Duwe G; Gaber A; Giessing M; Harke NN; Heidenreich A; Hijazi S; Hinkel A; Kaftan BT; Kheiderov S; Knoll T; Lümmen G; Peters I; Polat B; Schrodi V; Stolzenburg JU; Varga Z; von Süßkind-Schwendi J; Zugor V; Kowalski C
PLoS One; 2023; 18(12):e0295179. PubMed ID: 38039308
[TBL] [Abstract] [Full Text] [Related]
2. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N
Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394
[TBL] [Abstract] [Full Text] [Related]
3. Physicochemical and Biopharmaceutical Controllability of New Self-Assembled Fatty Acid Conjugated Leuprolide for the Enhanced Anticancer Activity.
Ngo HV; Bak HE; Nguyen HD; Lee KW; Park C; Lee BJ
Int J Nanomedicine; 2023; 18():2325-2344. PubMed ID: 37168738
[TBL] [Abstract] [Full Text] [Related]
4. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic prostate cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma TM; Sun Y; Malone S; Roach M; Dearnaley D; Pisansky TM; Feng FY; Sandler HM; Efstathiou JA; Syndikus I; Hall EC; Tree AC; Sydes MR; Cruickshank C; Roy S; Bolla M; Maingon P; De Reijke T; Nabid A; Carrier N; Souhami L; Zapatero A; Guerrero A; Alvarez A; Gonzalez San-Segundo C; Maldonado X; Romero T; Steinberg ML; Valle LF; Rettig MB; Nickols NG; Shoag JE; Reiter RE; Zaorsky NG; Jia AY; Garcia JA; Spratt DE; Kishan AU;
J Clin Oncol; 2023 Feb; 41(4):881-892. PubMed ID: 36269935
[TBL] [Abstract] [Full Text] [Related]
5. Radiotherapy activity in the COVID 19 pandemic: Brazil's operational national-level study.
Moraes FY; Gouveia AG; Lima RP; Bratti VF; Hamamura AC; Viani GA
J Cancer Policy; 2023 Jun; 36():100367. PubMed ID: 36216270
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the prostate fractionated irradiation trial - PROFIT.
Zhou K; Renouf M; Perrocheau G; Magné N; Latorzeff I; Pommier P; Créhange G; Paumier A; Bera G; Martin J; Catton C; Bellanger M; Supiot S
Radiother Oncol; 2022 Aug; 173():306-312. PubMed ID: 35772576
[TBL] [Abstract] [Full Text] [Related]
7. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract] [Full Text] [Related]
8. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract] [Full Text] [Related]
9. Using guideline-based clinical decision support in oncological multidisciplinary team meetings: A prospective, multicenter concordance study.
Ebben KCWJ; Hendriks MP; Markus L; Kos M; De Hingh IHJT; Oddens JR; Rothbarth J; De Wilt H; Strobbe LJA; Bessems M; Mellema CT; Siesling S; Verbeek XAAM
Int J Qual Health Care; 2022 Mar; 34(1):. PubMed ID: 35137091
[TBL] [Abstract] [Full Text] [Related]
10. Inhibitory effect of polyphenols (phenolic acids, lignans, and stilbenes) on cancer by regulating signal transduction pathways: a review.
Hazafa A; Iqbal MO; Javaid U; Tareen MBK; Amna D; Ramzan A; Piracha S; Naeem M
Clin Transl Oncol; 2022 Mar; 24(3):432-445. PubMed ID: 34609675
[TBL] [Abstract] [Full Text] [Related]
11. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries.
Wenzel M; Collà Ruvolo C; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Mandel P; Chun FKH; Karakiewicz PI
Cancer Epidemiol; 2021 Oct; 74():101994. PubMed ID: 34364187
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
[TBL] [Abstract] [Full Text] [Related]
13. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel.
Shi X; Fan J; Pei X; Wang Y; Guo G; Yang T; Wang X; He D; Li L
Andrologia; 2021 Jul; 53(6):e14064. PubMed ID: 33900646
[TBL] [Abstract] [Full Text] [Related]
14. A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.
Pandurangi RS; Tomasetti M; Verapazham ST; Paulmurugan R; Ma C; Rajput S; Anjanappa M; Nakshatri H
PLoS One; 2021; 16(2):e0225869. PubMed ID: 33556062
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of Serum Markers with Regard to treatment Procedures in Advanced Stage prostate cancer Patients.
Wolny-Rokicka E; Petrasz P; Krajewski W; Sulimiera Michalak S; Tukiendorf A
Med Sci Monit; 2020 Dec; 26():e925860. PubMed ID: 33326414
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
[TBL] [Abstract] [Full Text] [Related]
17. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized prostate cancer Following Radical prostatectomy.
Weiner AB; Faisal FA; Davicioni E; Karnes RJ; Griend DJV; Lotan TL; Schaeffer EM
Eur Urol Oncol; 2021 Dec; 4(6):955-962. PubMed ID: 32540218
[TBL] [Abstract] [Full Text] [Related]
18. Simultaneous Detection of Multiple Tumor Markers in Blood by Functional Liquid Crystal Sensors Assisted with Target-Induced Dissociation of Aptamer.
Qi L; Liu S; Jiang Y; Lin JM; Yu L; Hu Q
Anal Chem; 2020 Mar; 92(5):3867-3873. PubMed ID: 32069024
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of treatment (HEAT) registry.
Lovegrove CE; Peters M; Guillaumier S; Arya M; Afzal N; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Virdi J; Winkler M; Emberton M; Ahmed HU; Shah TT; Minhas S
BJU Int; 2020 Jun; 125(6):853-860. PubMed ID: 31971335
[TBL] [Abstract] [Full Text] [Related]
20. Ophiopogonin D' induces RIPK1‑dependent necroptosis in androgen‑dependent LNCaP prostate cancer cells.
Lu Z; Wu C; Zhu M; Song W; Wang H; Wang J; Guo J; Li N; Liu J; Li Y; Xu H
Int J Oncol; 2020 Feb; 56(2):439-447. PubMed ID: 31894265
[TBL] [Abstract] [Full Text] [Related]
[Next]
